BioCos

Project: Establishment of an integrative nutrigenomics platform for End Stage Renal Disease patients

Nutrigenomics is fundamental in the understanding of the dietary intake influence on phenotype, particularly of the silver population. The project aims to establish an integrative nutrigenomics platform from silver population of End Stage Renal Disease (ESRD) patients from Crete (Greece). To achieve this, BioCos will integrate omics data and dietary habits from healthy and kidney-failure individuals in order to assess the molecular mechanisms interacting with bioactive compounds and nutrients and detect putative biomarkers.

About BioCosBioCoS stands for “Bioinformatics and Computational Science” and their core business activity is to provide and commercialise Bioinformatic solutions in the biomedical and agri-food industry e.g., omics data, biomarkers, DNA traceabilty and authenticity of products.

Consortium

Sequentia Biotech SL Sequentia is a bioinformatics company that offers services and technologies that help transform genomic data into knowledge in academic research, plant and animal breeding, and biomedicine.

Foundation for Research and Techonology – Hellas Institute of Molecular Biology and Biotechnology (IMBB-FORTH)IMBB is one of the most prominent life science research institutions in Greece. IMBB’s main mission is to pursue cutting-edge research and promote scientific excellence.

Technological Educational Institute (T.E.I.) of Crete – Department of Nutrition & Dietetics The T.E.I. of Crete is a Public Educational Institute founded in 1983. The Institute is a part of the higher education system of Greece and it provides undergraduate and postgraduate education services.

By continuing to use the site, you agree to the use of cookies. more information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.